anti-tumor activity of dinuclear pyrazoratoplatinum complex
Project/Area Number |
22590045
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Physical pharmacy
|
Research Institution | Osaka University of Pharmaceutical Sciences |
Principal Investigator |
SATO Takaji 大阪薬科大学, 薬学部, 講師 (80257899)
|
Co-Investigator(Kenkyū-buntansha) |
ICHIKAWA Hayato 日本大学, 生産工学部, 助教 (10351488)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2010: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
Keywords | 制がん剤 / 白金 / シスプラチン / アポトーシス / がん / 白金錯体 |
Research Abstract |
[{cis-(NH3)2Pt(II)}2 (μ-OH)(μ-pz)](NO3)2 (AMPZ) is more effective in L1210 cell than cisplatin. However, the apoptosis induction potency of AMPZ was lower than that of cisplatin. In L1210, AMPZ led to G2 cell cycle arrest as well as cisplatin. In proteome analysis, annexin A1 was one of the most elevated proteins in the cell treated with cisplatin. Cytocrome C pathway apoptosis induction by cisplatin was markedly decreased in the cisplatin resistant cell. However, resistant cell did not alter the apoptosis and cell cycle arrest induced by AMPZ. These results suggest that cytocrome C is related to induction of apoptosis by cisplatin but not AMPZ.
|
Report
(4 results)
Research Products
(4 results)